Shares of Pfizer fell 3.28% to $39.77 at 13:22 EST on Monday, after three sequential sessions in a row of losses. The New York Stock Exchange is falling 0.11% to $14,339.70, following yesterday’s downward trend, This seems, up until now, a somewhat negative trend trading session today.
Pfizer’s last close was $41.12, 8.32% under its 52-week high of $43.08.
News about Pfizer today
Pfizer May offer shots to trial volunteers who received placebo. According to today’s article on Bloomberg Quint, "Pfizer Inc. and BioNTech SE may soon allow participants in its Covid-19 vaccine trial to learn whether they received a placebo, rather than the real thing, and get the actual shot if they wish.", "Pfizer’s emergency use application provided data from 37,586 volunteers, the majority of whom were in the U.S., according to the FDA. "
US covid-19 vaccinations to begin Monday as CDC recommends Pfizer vaccine. According to today’s article on Business Insider, "CNN reported that the first freight trucks carrying around 184,275 vials of the vaccine departed Pfizer’s facility in Kalamazoo, Michigan, on Sunday.", "The United States is likely to start Covid-19 vaccinations on Monday after Robert Redfield, the director of the Centers for Disease Control and Prevention or CDC, gave the approval for Pfizer- BioNTech’s COVID-19 vaccine, multiple reports said."
Pfizer, biontech covid-19 vaccine candidate study in Germany support safety profile. According to today’s article on MarketWatch, "The study’s result come as the companies’ vaccine is being distributed for use in the U.S. Shares of Pfizer rose 1.5% in premarket trading and BioNTech’s stock gained 0.9%, as futures for the S&P 500 tacked on 0.6%.", "Pfizer Inc. and its Germany-based partner BioNTech SE said overall results of a Phase 1/2 study in Germany of its COVID-19 vaccine candidate, BNT162b2, mirrored those from the U.S. study. "
Pfizer, biontech report data from german phase 1/2 trial with covid-19 vaccine candidate. According to today’s article on Business Insider, "Pfizer Inc. (PFE) and BioNTech SE (BNTX) reported additional data on neutralizing antibody and T cell responses from the phase 1/2 trial with BNT162b2 conducted in Germany. ", "BNT162b2 is an investigational COVID-19 vaccine developed by Pfizer-BioNTech. "
Pfizer’s sales growth is a negative 9.7% for the current quarter and a decline by 0.5% for the next. The company’s growth estimates for the current quarter and the next is a negative 9.1% and a negative 8.8%, respectively.
Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.
Pfizer’s Stock Top and Bottom Yearly Value
Pfizer’s stock is valued at $39.77 at 13:22 EST, under its 52-week high of $43.08 and way higher than its 52-week low of $26.45.
Pfizer’s Moving Average
Pfizer’s value is above its 50-day moving average of $37.15 and way higher than its 200-day moving average of $35.17.
Previous days news about Pfizer
Netanyahu will be first to get Pfizer vaccine in Israel. According to Bloomberg Quint on Wed Dec 9, "Israeli Prime Minister Benjamin Netanyahu said he’s going to demonstrate his faith in Pfizer Inc.’s coronavirus vaccine by being the first in the country to be inoculated."
U.k. says those with severe allergy shouldn’t get Pfizer jab. According to Bloomberg Quint on Wed Dec 9, "People with a significant history of allergies should not currently receive the Covid-19 vaccine from Pfizer Inc. and BioNTech SE, the U.K.’s National Health Service said, after two people experienced reactions from the shots.", "Pfizer and BioNTech said they’re supporting the MHRA in its investigation."
Head of FDA advisory panel predicts approval for Pfizer vaccine. According to The Wall Street Journal on Wed Dec 9, "”We’re not at the borderline on efficacy,” he added, referring to data from the vaccine’s makers- Pfizer Inc. and Germany’s BioNTech SE-showing the shot is 95% effective at protecting against Covid-19, significantly higher than the 50% minimum the FDA had said would be required for an emergency authorization.", "The committee has been reviewing the data from Pfizer’s trial since last week."
Canada approves Pfizer vaccine with first batch due next week. According to Bloomberg Quint on Wed Dec 9, "Canada’s public health authorities approved Pfizer Inc. and BioNTech SE’s coronavirus vaccine, the first such authorization in a country that’s secured more doses per person than any other around the world.", "The Pfizer vaccine is currently approved for adults over the age of 16 as clinical tests for children continue. "
Pfizer says some vaccine documents accessed in EMA cyberattack. According to Bloomberg Quint on Wed Dec 9, "Pfizer shares closed on Wednesday down 1.7% to $41.85 in New York.", "Both the Pfizer-BioNTech and Moderna two-dose vaccine regimens rely on a new technology known as messenger RNA. "
First u.s. shipments of Pfizer vaccine will be 2.9 million doses. According to Bloomberg Quint on Wed Dec 9, "Less than half of the available 6.4 million doses of Pfizer Inc.’s Covid-19 vaccine will be initially sent out to states, and 500,000 will be held separately in reserve by the government, according to a top official at Operation Warp Speed.", "In late November they were told 6.4 million doses of Pfizer’s vaccine candidate would be available at first, and 12.5 million of Moderna Inc.’s shot after it is authorized."
Pfizer shot gets FDA advisers’ nod as agency decision nears. According to Bloomberg Quint on Thu Dec 10, "Panel member Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, suggested Pfizer study use of the vaccine in people with serious allergies as it moves toward seeking full FDA approval if it does get emergency authorization.", "The committee of independent vaccine experts voted 17 to 4, with one abstention, that the benefits of the vaccine from Pfizer Inc. and BioNTech SE outweigh the risks for use in people ages 16 and older. "
Moderna offers u.s. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, "It’s an agreement that could turn out to be especially valuable if the White House is forced to wait for Pfizer to replenish its inventory. ", "The vaccine produced by Pfizer and German partner BioNTech SE is in the final stages of getting emergency authorization from the U.S. Food and Drug Administration, with an advisory panel to the agency meeting today. "
FDA nears Pfizer decision; Australia cancels order: virus update. According to Bloomberg Quint on Fri Dec 11, "The FDA intends to proceed toward emergency use authorization of the Pfizer-BioNTech vaccine, he said.", "A New York state panel of public-health advisers approved a Food and Drug Administration committee’s backing for emergency use authorization of the Pfizer Inc. and BioNTech SE vaccine, Governor Andrew Cuomo said on Twitter."
Pfizer vaccine clearance to be sought in Hong Kong after FDA nod. According to Bloomberg Quint on Fri Dec 11, "The Chinese company with the rights to market the Pfizer Inc.-BioNTech SE coronavirus vaccine in Hong Kong is preparing to seek approval of the shot soon after the U.S. clears it, according to people familiar with the matter.", "The EU is also reviewing the Pfizer-BioNTech shot and is expected to authorize it soon."
Pfizer raises quarterly cash dividend to 39 cents a share vs. 38 cents. According to MarketWatch on Fri Dec 11, "Pfizer Inc. said Friday’s its board has raised its quarterly cash dividend to 39 cents a share from 38 cents in the year-earlier period. ", "”It is expected that Viatris will begin paying a quarterly dividend in the second quarter of 2021, at which time Pfizer’s quarterly dividend will be reduced such that the combined dividend dollar amount received by Pfizer shareholders, based upon the combination of continued Pfizer ownership and approximately 0.124079 shares of Viatris which were granted for each Pfizer share in the spin-off, will equate to Pfizer’s dividend amount in effect immediately prior to the initiation of the Viatris dividend,” the company said in a statement. "
FDA aiming for quick authorization of Pfizer covid vaccine. According to Bloomberg Quint on Fri Dec 11, "Thursday’s FDA advisory panel discussion touched on incidents of Bell’s palsy, a temporary facial paralysis that was experienced by four people who received Pfizer’s vaccine in clinical trials. ", "Pfizer declined to comment. "
Pfizer vaccine cleared in u.s., a landmark in covid-19 fight. According to Bloomberg Quint on Sat Dec 12, "Pfizer didn’t study the vaccine in pregnant or lactating women, though the FDA is leaving it up to those women as to whether they will receive the vaccine. ", "Pfizer has developed special dry-ice containers to make it easier to store for facilities that don’t have the needed equipment."
Mexico approves Pfizer vaccine for emergency use as covid surges. According to Bloomberg Quint on Sat Dec 12, "Mexico’s health agency Cofepris approved Pfizer’s coronavirus vaccine for emergency use, Deputy Health Minister Hugo Lopez-Gatell said at a press conference Friday night.", "Mexico joins the U.K., Canada and the U.S. as countries that have granted emergency use of the Pfizer vaccine. "
Pfizer says prepared to deliver first doses of covid-19 vaccine in u.s. immediately. According to Business Insider on Sat Dec 12, "Pfizer Inc. (PFE) and BioNTech SE (BNTX) said Friday that they will begin delivering the first doses of their COVID-19 vaccine in the U.S. immediately, with delivery fulfillment expected to be completed in 2021.", "Pfizer will have marketing and distribution rights worldwide with the exception of China, Germany, and Turkey."
U.s. CDC committee of independent health experts recommends vaccination with Pfizer and biontech covid-19 vaccine for persons ages 16 years and older. According to Business Insider on Sat Dec 12, "The Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.", "These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; our contemplated shipping and storage plan, including our estimated product shelflife at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. "